TheStreet upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a c+ rating to a b- rating in a research report sent to investors on Friday, TheStreetRatingsTable reports.
A number of other research firms have also issued reports on JAZZ. HC Wainwright reiterated a hold rating and issued a $147.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, November 11th. Barclays lifted their price objective on Jazz Pharmaceuticals from $182.00 to $200.00 and gave the company an overweight rating in a research note on Monday. Sanford C. Bernstein reissued a market perform rating and set a $150.00 price objective on shares of Jazz Pharmaceuticals in a research report on Monday, October 14th. BidaskClub raised Jazz Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, November 27th. Finally, Oppenheimer set a $176.00 target price on shares of Jazz Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, September 26th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $168.71.
NASDAQ JAZZ opened at $150.38 on Friday. Jazz Pharmaceuticals has a 1-year low of $113.52 and a 1-year high of $154.44. The stock has a 50-day moving average of $132.43 and a two-hundred day moving average of $132.84. The company has a market cap of $8.55 billion, a P/E ratio of 12.29, a P/E/G ratio of 1.18 and a beta of 1.15. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.89 and a quick ratio of 3.71.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.19 by $0.91. The company had revenue of $537.70 million during the quarter, compared to analysts’ expectations of $523.92 million. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. The firm’s revenue was up 14.6% compared to the same quarter last year. During the same quarter last year, the company posted $3.58 EPS. On average, analysts anticipate that Jazz Pharmaceuticals will post 14.15 EPS for the current fiscal year.
In other news, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total value of $65,000.00. Following the completion of the sale, the chief executive officer now directly owns 311,855 shares of the company’s stock, valued at $40,541,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.30% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of JAZZ. Signaturefd LLC lifted its position in shares of Jazz Pharmaceuticals by 56.3% during the 2nd quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 72 shares during the period. MUFG Americas Holdings Corp acquired a new position in shares of Jazz Pharmaceuticals in the third quarter worth $29,000. Captrust Financial Advisors lifted its position in shares of Jazz Pharmaceuticals by 120.0% in the second quarter. Captrust Financial Advisors now owns 220 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 120 shares in the last quarter. Stonebridge Capital Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at $37,000. Finally, AdvisorNet Financial Inc acquired a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at $37,000. 89.10% of the stock is owned by institutional investors and hedge funds.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: What are benefits of a growth and income fund?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.